90Y-hMN14

N/A

Report date: 2025/11/24 17:27:23

Base Information

Drug Name90Y-hMN14
Drug Alias Name90Y-Humanized MN-14 IgGLabetuzumab Y-90Anti-CEA monoclonal antibody MN 14-Y-90IMMU-101hCEA-Y-90 +[6] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radionuclide Drug Conjugates +[5] 
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonists
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsPancreatic NeoplasmsRectal NeoplasmsColonic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenNetherlands +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsRectal NeoplasmsColonic Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A